Related Experiment Videos
Highlights in ovarian cancer
1Massachusetts General Hospital, Boston, Massachusetts 02114, USA. Seiden.Michael@MGH.Harvard.edu
The Oncologist
|August 31, 2000
Summary
The 2000 ASCO meeting showed no major ovarian cancer treatment shifts. New drugs like topotecan and gemcitabine were explored for advanced and recurrent ovarian cancer, with comparisons to standard therapies.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Clinical Trials
Background:
- The 2000 ASCO meeting reviewed current epithelial ovarian cancer (EOC) treatment strategies.
- No significant paradigm shifts in EOC management were presented.
- Focus remained on refining existing approaches and exploring novel agents.
Framework:
- Exploration of new chemotherapeutic agents including topotecan, oxaliplatin, doxil, and gemcitabine for advanced ovarian cancer.
- Evaluation of these agents as potential components of initial treatment regimens.
- Assessment of their tolerability and efficacy.
Implementation:
- Phase III studies comparing various chemotherapy strategies for recurrent ovarian cancer.
- Direct comparisons of single-drug versus two-drug salvage regimens.
- Investigation of alternative salvage schedules and agents for taxane- and platinum-resistant disease.
Implications:
- Identified active and tolerable chemotherapy regimens for advanced ovarian cancer.
- These regimens may warrant direct comparison with the established carboplatin and paclitaxel combination.
- Early-stage research into non-chemotherapeutic strategies for ovarian cancer was also presented.